Illumina Partners with Pharma Giants on Pan‑Cancer Companion Diagnostics Using TruSight Oncology
CompanyDeals

Illumina Partners with Pharma Giants on Pan‑Cancer Companion Diagnostics Using TruSight Oncology

AstraZeneca and Daiichi Sankyo Submit Priority‑Review sBLA for Enhertu as First‑Line Therapy for HER2‑Positive Breast Cancer
CompanyDrug

AstraZeneca and Daiichi Sankyo Submit Priority‑Review sBLA for Enhertu as First‑Line Therapy for HER2‑Positive Breast Cancer

Gan Lee Secures 3 B RMB Supply Deal for Insulin Glargine in Brazil’s National PDP
CompanyDeals

Gan & Lee Secures 3 B RMB Supply Deal for Insulin Glargine in Brazil’s National PDP

MicroTech Medical Secures NMPA Approval for Equil Patch Insulin Pump in Children and Adolescents
CompanyMedical Device

MicroTech Medical Secures NMPA Approval for Equil Patch Insulin Pump in Children and Adolescents

Biogen Receives FDA Complete‑Response Letter on High‑Dose Nusinersen for SMA
CompanyDrug

Biogen Receives FDA Complete‑Response Letter on High‑Dose Nusinersen for SMA

Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer’s Disease
CompanyDrug

Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer’s Disease

XtalPi and Bio‑Sincerity Announce AI‑Robotics R&D Partnership
CompanyDeals

XtalPi and Bio‑Sincerity Announce AI‑Robotics R&D Partnership

Prellis Biologics and Eli Lilly Announce AI‑Driven Antibody Discovery Collaboration
Others

Prellis Biologics and Eli Lilly Announce AI‑Driven Antibody Discovery Collaboration

Fosun Kairos Secures NMPA Approval for Second CAR‑T Product, FKC889, Targeting Relapsed/Refractory B‑Cell ALL
CompanyDrug

Fosun Kairos Secures NMPA Approval for Second CAR‑T Product, FKC889, Targeting Relapsed/Refractory B‑Cell ALL

Mabwell Bioscience Hits Phase II Milestone with First‑Patient Dose of 9MW3011, the Only Anti‑TMPRSS6 Monoclonal Antibody for Polycythemia Vera
Drug

Mabwell Bioscience Hits Phase II Milestone with First‑Patient Dose of 9MW3011, the Only Anti‑TMPRSS6 Monoclonal Antibody for Polycythemia Vera

Burning Rock Secures Japanese Approval for OncoGuide OncoScreen Plus CDx, Enabling Capivasertib Therapy
Medical Device

Burning Rock Secures Japanese Approval for OncoGuide OncoScreen Plus CDx, Enabling Capivasertib Therapy

FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer
CompanyDrug

FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer